Drugs / AMG 108
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT00369473 | Sep 2006 → Jun 2008 | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00293826 | Mar 2006 → Nov 2007 | rheumatoid arthritis | Amgen | Completed | Met primary |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00661921 Comparator | Jun 2008 → Jun 2009 | type 2 diabetes mellitus | Amgen | Withdrawn | No outcome recorded |
| Phase 2 | NCT00110942 Comparator | Feb → Jun 2005 | osteoarthritis | Amgen | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00661921 ↗ |
| Action | Inhibit | “inhibiting the activity of IL-1a and IL-1b” PMID 21801403 ↗ Jul 2011 |
| Modality | Monoclonal antibody | “AMG 108 is a fully human, immunoglobulin subclass G2 (IgG2) monoclonal antibody” PMID 21801403 ↗ Jul 2011 |
| Route | Subcutaneous | “patients received placebo or 300 mg AMG 108 SC, once every 4 weeks for 12 weeks.” PMID 21801403 ↗ Jul 2011 |
| Target | IL1R1 | “binds the human interleukin-1 (IL-1) receptor type 1” PMID 21801403 ↗ Jul 2011 |